Pregio Pharma - Due diligence report

A 360° intelligence report on Pregio Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …

2011-03-30 Chennai, Tamil Nadu Active Unlisted Active Compliant
Share
Connect MCP
PP Pregio Pharma
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pregio Pharma — 360° Intelligence Report

Generated from MCA filings & public records
82/100
Trust Score
Low Risk

Pregio Pharma is assessed as Low Risk with a Trust Score of 82/100. Pregio Pharma is an active private limited indian non-government company incorporated in 2011, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 03 Oct 2026 from the latest processed filings. Pregio Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
61/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 70/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (12.20 cr) · 2 satisfied (8.40 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Indian Overseas Bank2 48.0 cr
The South Indian Bank Limited1 48.0 cr
Others1 48.0 cr
Compliance Score: 61/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • Litigation present in 2 court forum(s).
  • 2 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
VISWANATHAN PALANIAPPAN 01234567 Director 01/04/2018 6 yrs Approved
RANGANATHAN KUPPAN 01234567 Director 01/04/2018 6 yrs Approved
MUTHUVELAYUDHAM SIVAKUMAR 01234567 Director 01/04/2018 6 yrs Approved
SASIKUMAR 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
11 allotment(s) · 8 transfer(s)

Promoters hold a minority stake - exact percentages are part of the full report.

Key managerial personnel: RANGANATHAN KUPPAN (CFO) · MUTHUVELAYUDHAM SIVAKUMAR (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 15+ years.
Active GST registration(s).
Distress signals & risk flags
Statutory filings appear overdue.
2 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment75/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 12.20 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
06 Jan 2025
Director ceased
VISWANATHAN PALANIAPPAN
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
21 Nov 2023
Charge created
Indian Overseas Bank - 8.03 Lakh
01 Sep 2023
Director appointed
RANGANATHAN KUPPAN (CFO)
17 Aug 2023
Charge satisfied
The South Indian Bank Limited
16 Aug 2023
Director appointed
VISWANATHAN PALANIAPPAN (Company Secretary)
28 Jul 2023
Charge created
Indian Overseas Bank - 12.12 cr
31 Mar 2023
Share transfer (FY 2023)
200000.00000000 shares to PADMAGAYATHRI BALASUBRAMANIAN
Share transfer (FY 2023)
600000.00000000 shares to SUBBAIAH BALASUBRAMANIAN
Share transfer (FY 2023)
551392.00000000 shares to ARUMUGAM SARAVANAN
Share transfer (FY 2023)
750000.00000000 shares to SUBRAMANIAN MURALI
Share transfer (FY 2023)
748839.00000000 shares to SUJATHA MURALI
04 Nov 2022
Director ceased
DEIVASIGAMANI SHANMUGA SUNDARAM
11 Jun 2022
Director ceased
MOHANRAJULU SRINIVASA NAIDU
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Promoters hold a minority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 11 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
H B R Chemicals Private Limited U24229DL1979PTC009433 Delhi, Delhi, India
Vop Flavours And Fragrances Private Limited U24304UP2020PTC146759 Noida, Uttar Pradesh, India
Supraveni Chemicals Private Limited U02411KA2003PTC032925 Bangalore, Karnataka, India
Mcon Rasayan L24304MH2016PLC286140 Mumbai, Maharashtra, India
Qv Labs Private Limited U24233GJ2006PTC048583 Ankleshwar, Gujarat, India
Spannkraft Hydrosystems Private Limited U51507MH2006PTC166042 Nagpur, Maharashtra, India
Konar Organics Limited U24230TG1988PLC008215 Hyderabad, Telangana, India
Victor Bio Genetics Private Limited U74999TG2018PTC123961 Secunderabad, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pregio Pharma before audits and certifications: compliance score 61/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pregio Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Pregio Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Pregio Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Pregio Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pregio Pharma an active company?

Pregio Pharma has MCA status “Active” with a compliance score of 61/100 (Moderate).

Is Pregio Pharma financially healthy?

Pregio Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Pregio Pharma?

Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pregio Pharma?

Promoters hold a minority stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Pregio Pharma have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.

Is Pregio Pharma up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 61/100 (Moderate).

Is it risky to lend to Pregio Pharma?

Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.